An experimental medication shows promise in slowing the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, according to recently released results from a clinical trial run by Harvard Medical School investigators based at Massachusetts General Hospital and colleagues at Amylyx Pharmaceuticals, the company that manufactures the medication and that helped fund the study.
— Read on hms.harvard.edu/news/als-milestone